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Epilepsy is a worldwide, chronic, multifactorial neuro-
logical disorder affecting over 50 million people1.
The mean prevalence rate for active epilepsy in devel-
oped countries varies between 4 and 10 per 1000 2. In a 
systematic review by Forsgren3 it was found that the range 
for prevalence rates in Europe was 3.3−7.8 per 1000 with 
a median prevalence rate of active epilepsy 5.2 per 1000. 
Higher prevalence rates have been reported from resource 
poor countries, ranging from 10 to 40‰4. Regardless of 
apparent disparities among rich and resource poor coun-
tries, these numbers clearly show the enormous socioeco-
nomic burden epilepsy carries with itself.
The data from some eastern Mediterranean countries 
are missing including Montenegro. Epidemiological data 
on epilepsy are defi cient and currently national registry 
as well as control program are lacking. Population based 
prevalence study from neighboring Croatia suggests prev-
alence rates between 4.8 and 5.5/1000, which is in accor-
dance to the fi ndings from other European countries5. 
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A B S T R A C T
The purpose of this study was to assess for the fi rst time the prevalence of epilepsy in the capital of Montenegro and to 
describe the clinical and epidemiological profi le of the disorder. A door-to-door screening was performed on population 
of 6 randomly selected areas of Podgorica (capital of Montenegro) using validated screening questionnaire. In phase 1, 
the screening by questionnaire of 4007 individuals identifi ed 307 suspected cases of epilepsy. Four of them dropped out of 
further investigation just before entering the phase 2. In phase 2, the remaining 303 suspected cases were fi rst examined 
by general practitioner and then by an epileptologist, on two follow-up visits. The confi rmation of epilepsy was based on 
clinical examination. Electroencephalogram (EEG), computed tomography (CT) and/or magnetic resonance imaging 
(MRI) were also used, resulting in 29 persons being diagnosed with epilepsy. An overall prevalence of 7.2 cases per 1000 
inhabitants was calculated (CI 95% 5.0–10.0). Majority of them had been previously diagnosed (86.20%), 27 had active 
epilepsy and over a half of them had multiple antiepileptic drugs (65.51%). Referring to the 27 patients with active epi-
lepsy, the predominant seizure type was focal (all types) in 14 (48.27%), generalised idiopathic seizures in 11(37,93%) and 
undetermined in 2 (6.89%). Cause of epilepsy was known in 10 patients. EEG abnormalities were found in almost all 
patients (89.65%). CT anomaly was determined in 9 whereas only 1 patient had an abnormal MRI fi nding. The esti-
mated prevalence of epilepsy indicated higher rates compared to neighboring counties and the rest of the Europe, but 
limitations of the study (high rejection rate and stigma) should be taken into consideration.
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Introduction
Montenegro is in many aspects very similar to Croatia 
suggesting that similar prevalence rates are to be expected.
The aim of this study was to obtain for the prevalence 
rate of epilepsy in the capital of Montenegro and to de-
scribe the clinical and epidemiological profi le of the disor-
der.
Methods
We conducted a door-to-door survey in six areas: four 
urban and two rural areas of Podgorica in order to inves-
tigate the prevalence of epilepsy. These areas were gener-
ally chosen because they included different socioeconomic 
classes and local health centers were easily assessable. 
The population of Podgorica, the capital of Montenegro, is 
about 185.000 people which is 30% of total Montenegrin 
population6.
Our sample included only participants aged 18 to 80 
years of age, which constitute around 130.000 people. 
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Written informed consent was obtained from all subjects 
who were willing to participate to enrolment. A person 
who answered positively to at least one of the 13 questions 
of the screening questionnaire (Table 1) was considered as 
a suspected epilepsy case.
TABLE 1
SCREENING QUESTIONNAIRE FOR EPIDEMIOLOGY OF EPILEPSY




1. Have you ever had attacks of shaking of the arms or legs which you could not control?
2. Have you ever had attacks in which you fall and become pale?
3. Have you ever lost consciousness?
4. Have you ever had attacks in which you fall with lost consciousness?
5. Have you ever had attacks in which you fall and bite your tongue?
6. Have you ever had attacks in which you fall and lose control of your bladder?
7. Have you ever had brief attacks of shaking or trembling in one arm or leg or in face?
8. Have you ever had attacks in which you lose contact with the surroundings and experience abnormal smells?
9. Have you ever been told that you have or had epilepsy or epileptic fi ts?
10. Have you ever had attacks in which you lose contact with your surroundings and experience a sensation in which objects change 
shape or size?
11. Did you ever have attacks of convulsions in fever before the age of 5?
12. Have you ever suddenly in a daze or amazement, lost something from your hand during an activity, writing or eating?
13. Have you ever had suddenly in a daze, smack, purposeless activity of hands which you subsequently have no memory?
For those with defi nite or possible epilepsy:
1.  Onset age:‗‗‗‗‗
2.  Number of attacks:
 Recent 1 year:   =have attacks (____times); =no attack
 Recent 2 years: =have attacks (____times); =no attack
 Recent 5 years: =have attacks (____times); =no attack
3.  Are there any causes of attack? ____________________________________________
4.  Did the patient take any treatment?
 (1) Never accepted any treatment: 1 = Yes; 2 = No
 (2) To be Treated: 1 = Yes; 2 = No
  If answer yes: 1 = Western medicine; 2 = Traditional medicine
  Drug name and dosage: ____________________________________________
  Effect: 1 = Excellent; 2 = Good; 3 = No effect
  Treatment assessment: 1 = Regular; 2 = Irregular
 (3) Last week: 1 = treatment; 2 = Not treatment




1 = Diagnose epilepsy     2 = Excluded epilepsy
Seizure type:
1. Simple Partial Seizures     2. Complex Partial Seizures     3. Secondarily Generalized Seizures
4. Generalized Tonic-clonic seizures     5. Absences     6. Others (Myoclonic, Atonic etc)
Checked by Dr.__________________ Date:______________
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Clinical and epidemiological defi nitions
Following defi nitions were used to classify epilepsy as 
well as types of medication in all cases:
1. Epilepsy was defi ned as a condition characterized 
by recurrent epileptic seizures, unprovoked by any 
immediate identifi ed cause. Multiple seizures occur-
ring in a 24-hour period were considered as a single 
event. An episode of status epilepticus was consid-
ered as a single event. Individuals who had had only 
febrile seizures, seizures during pregnancy, or sei-
zures due to alcohol or substance abuse or acute 
psychiatric illness were excluded from this category.
2. Active epilepsy: any patient who has had recurrent 
unprovoked seizures with an interval between them 
of 24 hours or more in the previous 12 months.
3. Inactive epilepsy: any patient who has had recurrent 
unprovoked seizures with an interval between them 
of 24 h or more, but who has been seizure-free for 
the previous 36 months.
4. Adequate epilepsy treatment: any patient with ac-
tive epilepsy regularly using appropriate antiepilep-
tic drugs (AEDs) as mono-or polytherapy at stan-
dard dosage is defi ned as having adequate epilepsy 
treatment 7
5. Monotherapy: any patient who is taking just one 
AED is defi ned as taking monotherapy.
6. Polytherapy: any patient who is taking more than 
one AED is defi ned as taking polytherapy.
Design of a study
A two phase approach was used to identify patients 
with epilepsy (Figure 1):
Phase 1 – through a door-to-door survey a screening 
questionnaire was used to identify potential patients with 
epilepsy. This phase was carried out between June and 
December 2013. For this survey, we used a validated epi-
demiological questionnaire (with sensitivity 95.8% and 
specifi city 97.8%) for the identifi cation of cases of epilepsy 
8. During a door- to-door survey all inhabitants of selected 
six areas were interviewed by a trained medical doctor. 
They made sure that participants understood all the ques-
tions, they provided additional explanations but were not 
allowed to infl uence the answers of participants in any 
way. Name, age, gender, address and telephone number 
were taken from all interviewed participants for the pur-
pose of further investigation. Each sheet had its code and 
those codes were given to the participants.
If no response was obtained on the fi rst visit to a fl at 
or a house, two further visits were made and if still there 
were no response the unit was considered as nonrespon-
sive. Also if participants did not want to participate, even 
after detailed oral explanation, were also considered non-
responsive.
Phase 2 – in the fi rst step of phase 2 those who screened 
positive in phase 1 were sent to the nearest general 
practitioner, who performed routine physical examination 
as well as biochemistry analysis in order to rule out other 
diagnosis which can mimic epilepsy. Those who were still 
considered as possible patients with epilepsy were then 
sent to a neurologist, trained in epilepsy, to confi rm or 
refuse the diagnosis based on clinical examination and 
detailed interview (second step of phase 2).
An EEG (standard and prolonged recording; Nicolet 
One® EEG) was performed in all patients, as well as CT 
(Siemens). MRI (Siemens, 1.5 Tesla) was done in all 
patients with negative CT. Clinical examination and 
imaging were completed on initial visit and on second 
follow up fi nal diagnosis was made. People not diagnosed 
as having epilepsy were considered false positive.
Statistics
Data were coded and entered into the computer using 
Excel Programme and were analyzed by “Statistical Pack-
age for Social Sciences” (SPSS) 16.0 statistical software. 
(SPSS Inc., Chicago, IL). Prevalence was estimated on the 
basis of the number of true positive cases divided by total 
number of people studied expressed as n/1.000 (with a 95% 
confi dence interval estimated using Wilson’s method). The 
results are presented using means and frequencies.
Results
In a phase 1 a total of 4007 people were interviewed. 
Rejection rate was very high (43% of all subject were 
willing to participate), especially among suburb. The 
mean age of participants was 39.18+/–19.33 (SD) with 
majority of participants being female (63.1%). 2272 (56.7%) 
interviewees screened positive.
In a fi rst step of phase 2, all participants who screened 
patients were seen by a general practitioner who referred 
306 (7.6%) to an epileptologist as a potential cases of 
epilepsy. Four patients dropped out from further in ves-
Fig. 1. Screening survey about epilepsy conducted in Podgorica, 
Montenegro.
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tigation. A neurologist evaluated the diagnosis in 
remaining 303 subjects, identifying 29 patients as true 
positive. Thus, from a study population of 4007, 29 patients 
with epilepsy were identifi ed yielding an overall prevalence 
of 7.23% (95% CI 5.0–10.0). Majority of patients (86.2%) 
had already been diagnosed with epilepsy and the 
remaining 4 had inactive epilepsy. Twenty two patients 
(75.8%) were diagnosed after fi rst confi rmation visit and 
7 patients after the second.
Nineteen of 29 patients were female (65.5%). The mean 
age of patients was 43.1+/–18.1 (SD). The most frequent 
age range among patients with epilepsy was 18–34, as 
well as over 65. Socio-demographic characteristics of 
patients with epilepsy are given in Table 2.
In regard to etiologic classifi cation, the cause of epi-
lepsy was found in just over a third of patients (34.4%). 13 
patients (44.8%) had idiopathic generalized syndrome 
while 6 patients (20.6%) had cryptogenic epilepsy. The 
causes of symptomatic epilepsy in our sample were the 
following: stroke (30%), primary brain tumor and trauma-
tic brain injury (20% respectively), metastases, encepha-
litis and congenital anomalies (10% respectively). Five 
patients with idiopathic generalised syndrome had a fa-
mily history of epilepsy.
Focal epilepsy (all types, 14 patients, 48.2%) was more 
common than generalised epilepsy (13 patients, 44.85%). 
The remaining 2 cases (6.8%) could not be classifi ed as 
either generalized or partial using ILAE classifi cation 9. 
Among patients with partial seizures the most common 
type was complex partial seizures (9 patients, 64.2%). 
They were more likely to be found among older. In one 
patient with a generalised tonic-clonic seizure, the use 
prolonged EEG recording that the seizure had a focal on-
set.
Epileptiform EEG changes were found in 26 epilepsy 
patients. CT revealed abnormalities in 9 patients (31%). 
In 3 cases CT with application of contrast was performed 
in order to reveal the etiology of seizures. MRI was per-
formed in 14 patients but only one patient had MRI abnor-
mality found.
Twenty seven patients (93.10%) had active epilepsy. 
The mean duration of epilepsy was 6.24+/– 4.13 years 
(SD). Over 60% of patients were on multiple antiepileptic 
drugs. The most frequently used antiepileptic drugs 
(AED) were phenobarbital, carbamazepine, sodium val-
proate, lamotrigin, topiramate and levetiracetam. The 
most common combination of AEDs were sodium valpro-
ate and topiramate, topiramate and lamotrigine, carbama-
zepine and topiramate, carbamazepine and levetiracetam, 
sodium valproate and levetiracetam.
Discussion and Conclusion
This study was designed to provide the fi rst prevalence 
rate on epilepsy in Podgorica, Montenegro.
Our door-to-door survey revealed a prevalence of 
epilepsy among the interviewed population of 7.2 cases per 
thousand. Compared to some 5–10 but not all parts of 
neighboring Croatia 15 and other more developed European 
countries,11–14 our results showed a pattern towards higher 
prevalence. We feel that this result is rather due to low 
sample size owing to low willingness to participate and 
compliance of interviewees, especially in rural areas. Just 
over 43% of all inhabitants were willing to take the survey. 
Majority of those who were fi nally confi rmed as epilepsy 
cases had already been diagnosed. We believe that stigma 
and prejudice were the possible explanations for the low 
response rate.
Distribution of our patients with epilepsy was bi no-
minal, with the majority of patients being in their third or 
fourth decade of life and older than 65. This result is in 
accordance with the fi nding of Hauser18, although Mon-
tenegro is more of a developing country which by literature 
shows a different distribution pattern.
The cause of epilepsy was found in over a third of 
patients (34.4%). Well defi ned risk factors like stroke and 
traumatic brain injuries were found in half of these 
patients, predominantly male. Our result thus supports 
TABLE 2









18–24   6 (20.69%)
25–34   6 (20.69%)
35–44   4 (13.79%)
45–54  2 (6.90%)
55–64   4 (13.79%)
>65   7 (24.14%)
Level of education  
Elementary school   6 (20.69%)
Secondary school 14 (48.28%)
Faculty   9 (31.03%)
Employment  
Employed   8 (27.58%)
Unemployed 14 (48.28%)
Retired   7 (24.14%)
Marital status  
Married (female)   5 (17.24%)
Married (male)   5 (17.24%)
Single (female) 13 (44.83%)
Single (male)   4 (13.79%)
Divorced  1 (3.45%)
Widower  1 (3.45%)
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fi ndings from other bigger surveys which concluded that 
stroke12,19–20 and especially TBI contribute to the 
occurrence of seizures and epilepsy.
The predominant seizure types among our patients 
were partial seizures, predominantly among older. The 
pattern observed in the distribution of localization-relat-
ed, generalized and undetermined epilepsies among cases 
in this sample is consistent French21, Swedish12 and Finn-
ish13.
Over 90% of diagnosed patients had active epilepsy and 
they were all under treatment. Unlike many resource poor 
and developing countries22 antiepileptic drugs are not lim-
ited in Montenegro. Any patient with a diagnosis of epi-
lepsy will be provided with AED, free of charge, even with 
new AEDs like levetiracetam and pregabalin. This result 
would therefore suggest that treatment gap does not exist 
in Montenegro. However, authors disagree. Treatment gap 
is a global problem and regardless of reason even a small 
percentage of people with epilepsy, at least initially, would 
be left untreated.
This was a fi rst study to estimate the prevalence of 
epilepsy is Montenegro. It was performed using a door-to-
door screening procedure, an approach promoted by Inter-
national League Against Epilepsy.17 However, the power 
of the study is limited by the low response rate of inter-
viewees. The study showed a pattern towards higher 
prevalence of epilepsy, although in many other aspects the 
results were in according to those reported from similar 
studies. Study also brought to light the inevitable problem 
of stigmatization, probably resulting in low participation 
rate. Capture-recapture technique should be implemented 
in future in order to yield more precise prevalent rate. 
Also, information campaigns should be enforced in order 
to fi ght stigma and build basis for better community 
health.
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RASPROSTRANJENOST EPILEPSIJE U PODGORICI (CRNA GORA)
S A Ž E T A K
Svrha ovog istraživanja bila je po prvi puta procijeniti učestalost epilepsije u glavnom gradu Crne Gore i opisati 
klinički i epidemiološki profi l poremećaja. Istraživanje od vrata do vrata je provedeno na populaciji od 6 slučajno odab-
ranih područja Podgorice (glavni grad Crne Gore), uz upotrebu potvrđenih upitnika. U fazi 1, selektiranjem pomoću 
upitnika od 4007 osoba identifi cirano je 307 osoba na koje se sumnjalo da pate od epilepsije. Četvero od njih je odustalo 
iz daljnje istrage neposredno prije ulaska u fazu 2. U fazi 2, preostalih 303-oje sumnjivih slučajeva su prvo pregledane 
od strane liječnika opće prakse, a zatim od strane epileptologa u još dva navrata. Potvrda epilepsije temeljila se na 
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kliničkom pregledu. Elektroencefalogram (EEG), kompjutorizirana tomografi ja (CT) i / ili magnetska rezonancija (MRI) 
su također korišteni, što je rezultiralo s dijagnozom epilepsije kod 29 osoba. Ukupna učestalost od 7,2 slučajeva na 1000 
stanovnika je izračunata (CI 95% 5.0–10.0). Većina od njih je već prethodno bila dijagnosticirana (86,20%), 27 je imalo 
aktivnu epilepsiju i više od polovice ispitanih su korstili više vrsta antiepileptika (65,51%). Pozivajući se na 27 bolesnika 
s aktivnom epilepsijom, tip napadaja koji je prevladavao je bio žarišni (sve vrste) kod 14 ispitanika (48,27%), general-
izirani napadaji idiopatska kod 11 ispitanika (37,93%), te neutvrđeni kod 2 ispitanika (6,89%). Uzrok epilepsije je poznat 
kod 10 bolesnika. EEG abnormalnosti nađene su kod gotovo svih bolesnika (89,65%), a CT anomalija utvrđena je kod 9, 
dok je samo jedan bolesnik imao abnormalan MRI nalaz. Procijenjena prevalencija epilepsije pokazala veće stope u us-
poredbi sa susjednim županijama i ostatka Europe, ali ograničenja istraživanja (visoka odbacivanje stopa i stigma) 
treba uzeti u obzir.
